Literature DB >> 35196364

Correction: Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.

.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0259936.].

Entities:  

Year:  2022        PMID: 35196364      PMCID: PMC8865660          DOI: 10.1371/journal.pone.0264610

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


There is an error in the seventh sentence of the abstract. The correct sentence is: From 2005–2009 to 2015–2019, the median monthly product price over all distinct indications of all products decreased by 7.56% (CHF 5,699 [interquartile range 4,483–7,321] to CHF 5,268 [4,019-6,967]), whereas it increased by 73.7% for monoclonal antibodies. The ORCID iD is missing for the second author. Author Christoph Jakob Ackermann’s ORCID iD is: 0000-0003-2621-5512 (https://orcid.org/0000-0003-2621-5512). The publisher apologizes for the errors.
  1 in total

1.  Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.

Authors:  Yael Rachamin; Christoph Jakob Ackermann; Oliver Senn; Thomas Grischott
Journal:  PLoS One       Date:  2021-11-15       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.